Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...

Merck is strengthening its semiconductor manufacturing footprint in South Korea with a new molybdenum production facility designed to accelerate next-generation chip development, secure local supplies ...

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma ...

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with ...

Merck's Courtney Ronaldo discusses the strategy behind the company's new oncology campaign, its multichannel presence at ESMO ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

The results, which triggered Moderna's stock to drop, are "really encouraging," says Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, a nonprofit. This kind of mRNA cancer vaccine ...

Moderna and Merck's personalized mRNA vaccine, combined with Keytruda, reduces melanoma recurrence or death risk in Phase 3 ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...